Something went wrong with the connection!

Boisenews Now

Acute Respiratory Distress Syndrome Market is expected to show positive growth, during the forecast period of 2019 to 2032, DelveInsight

 Breaking News
  • No posts were found

Acute Respiratory Distress Syndrome Market is expected to show positive growth, during the forecast period of 2019 to 2032, DelveInsight

July 28
20:30 2022
Acute Respiratory Distress Syndrome Market is expected to show positive growth, during the forecast period of 2019 to 2032, DelveInsight

Acute Respiratory Distress Syndrome Market Insights report from DelveInsight provides a thorough understanding of the Acute Respiratory Distress Syndrome Market size by treatment, epidemiology, emerging therapies, market share of the various therapies, and the current and forecasted Acute Respiratory Distress Syndrome Market size from 2019 to 2032 divided into the 7MM (the USA, EU5 (Germany, France, Italy, Spain, and the UK), and Japan) regions.

 

Acute Respiratory Distress Syndrome Overview

Acute respiratory distress syndrome (ARDS) is a rapidly progressive disease occurring in critically ill patients. The major complication in ARDS is marked by leakage of fluid into the lungs, making breathing difficult or impossible.

 

Download Sample Report- https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-market

 

Regions covered in the report

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

 

Key highlight of the Acute Respiratory Distress Syndrome Market Report

  • As per DelveInsight, the total Acute Respiratory Distress Syndrome incident population in the 7MM was observed to be 1,267,192 cases in the year 2021.
  • DelveInsight estimates show a higher incidence of Acute Respiratory Distress Syndrome in the United States, with an estimated number of approximately 704,707 cases in the year 2021.
  • According to DelveInsight, the percentage of cases of Acute Respiratory Distress Syndrome are equal in both genders.

 

Acute Respiratory Distress Syndrome Epidemiology Insights

Acute Respiratory Distress Syndrome is characterized by an acute, diffuse, inflammatory lung injury, leading to increased alveolar-capillary permeability, increased lung weight, and loss of aerated lung tissue. Clinically, this establishes as hypoxemia, with bilateral opacities on chest radiography, associated with reduced lung compliance and increased venous admixture and physiological dead space. Morphologically, diffuse alveolar damage is observed in the acute phase of ARDS.

 

Acute Respiratory Distress Syndrome Epidemiology Segmentation in the 7MM

  • Total Acute Respiratory Distress Syndrome Incident Population
  • Acute Respiratory Distress Syndrome Severity-specific Cases
  • Acute Respiratory Distress Syndrome Incident Cases by Risk Factors

 

Do you want to know more information related to report? If yes, visit here- https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-market

 

Acute Respiratory Distress Syndrome Treatment Market

Acute respiratory distress syndrome treatment is supportive and includes mechanical ventilation, prophylaxis for stress ulcers and venous thromboembolism, nutritional support, and treatment of the underlying injury. Low tidal volume, high positive end-expiratory pressure, and conservative fluid therapy may improve outcomes. It is important to identify and treat any underlying infections with antibiotics targeted at culture sensitivities. Despite decades of research, treatment options for ARDS are restricted. Supportive care with mechanical ventilation remains the mainstay of management.

 

Acute Respiratory Distress Syndrome Market Insights

In Acute respiratory distress syndrome, the evolution of systemic and pulmonary inflammation in the 1st week of mechanical ventilation determines the physiologic progression (resolving vs unresolving) and the outcome of the disease. Glucocorticoids as end-effectors of the hypothalamic-pituitary-adrenal axis are the most important physiologic inhibitors of inflammation, affecting hundreds of genes involved in stress-related homeostasis. At the cellular level, glucocorticoids exert their effects by activating cytoplasmic heat shock protein-complexed glucocorticoid receptors, which in turn, interact with activated nuclear factor-κB to prevent DNA binding and subsequent transcriptional activity.

 

Acute Respiratory Distress Syndrome Market Size

The Acute Respiratory Distress Syndromemarket size in the seven major markets was approximately USD 1,354.7 million in 2021, which is further expected to increase by 2032

 

Acute Respiratory Distress Syndrome Market Forecast

Despite decades of research, treatment options for ARDS are restricted. Supportive care with mechanical ventilation remains the mainstay of management. There are relatively few treatments available for ARDS. Other treatment options, which the patients with ARDS are subjected to generally include supplemental oxygen, prone positioning, use of paralytics, fluid management, and a technique called positive end-expiratory pressure (PEEP) to help push the fluid out of air sacs. These are combined with continuing treatment of the original illness or injury. Because people with ARDS are less-abled to fight lung infections, they may develop bacterial pneumonia during the illness. Antibiotics are given to fight infection. Also, supportive treatment, such as intravenous fluid or food, may be needed.

 

Acute Respiratory Distress Syndrome Emerging Therapies

Expected launch of emerging therapies, such as EB05 (Edesa Biotech/Light Chain Bio), DB- 001 (Direct Biologics), BIO-11006 (BioMarck Pharmaceuticals), MultiStem (Athersys/Healios), Alteplase (Boehringer Ingelheim/Genentech), and Lucinactant (Windtree Therapeutics) etc. shall further create a positive impact on the market.

 

Request Sample Report- https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-market

 

Table of Content

1. Key Insights

2. Report Introduction

3. Acute Respiratory Distress Syndrome Market Overview at a Glance

4. Acute Respiratory Distress Syndrome Market: Future Perspective

5. Executive Summary of Acute Respiratory Distress Syndrome

6. Key Events

7. Disease Background and Overview

8. Epidemiology and Patient Population

9. Patient Journey

10. Off-Label Therapies for ARDS

11. Emerging Drugs

12. Acute Respiratory Distress Syndrome: Seven Major Market Analysis

13. Key Opinion Leaders’ Views

14. Market Drivers

15. Market Barriers

16. SWOT Analysis

17. Reimbursement and Market Access

18. Unmet Needs

19. Appendix

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

 

Do you have any query related to report? If yes, visit here- https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-market

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles

Categories